Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck.

Audrey HumphriesConnie J ZhouMadeleine WelshMelinda LemHyunseok KangAlain P Algazi

Published in: Head & neck (2023)

Carboplatin/paclitaxel can induce objective responses in patients with prior treatment with ICI and clinical outcomes in this small series compare favorably to those seen in ICI naïve patients.

Keyphrases

squamous cell carcinoma
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
small cell lung cancer
phase ii study
peritoneal dialysis
prognostic factors
clinical trial
patient reported outcomes
mesenchymal stem cells
cell therapy